Description: Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Home Page: www.orexo.com
Rapsgatan 7E
Uppsala,
Sweden
Phone:
46 1 87 80 88 00
Officers
| Name | Title |
|---|---|
| Mr. Nikolaj Sorensen | President & CEO |
| Mr. Fredrik Jarrsten | Executive VP & CFO |
| Ms. Cecilia Coupland | Senior VP & Head of Operations |
| Lena Wange | Investor Relations & Communications Director |
| Mr. Robert Ronn | Senior VP and Head of R&D |
| Dr. Edward Kim M.B.A., M.D. | Chief Medical Officer |
| Mr. Robert A. Deluca | President of Orexo US Inc |
| Mr. Jesper Lind | Advisor |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 9.7466 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 19.8524 |
| Price-to-Sales TTM: | 0.0756 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 113 |